A
163.32
-0.84 (-0.51%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Ascendis Pharma A/S | 看涨 | 看涨 |
AIStockmoo 评分
3.1
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 3.13 |
|
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.78% |
| 机构持股比例 | 113.63% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 307.00 (UBS, 87.98%) | 购买 |
| 中 | 250.00 (53.07%) | |
| 低 | 203.00 (Cantor Fitzgerald, 24.30%) | 购买 |
| 平均值 | 249.36 (52.68%) | |
| 总计 | 11 购买 | |
| 平均价格@调整类型 | 183.81 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Cantor Fitzgerald | 08 Aug 2025 | 203.00 (24.30%) | 购买 | 191.49 |
| Citigroup | 08 Aug 2025 | 290.00 (77.57%) | 购买 | 191.49 |
| 11 Jul 2025 | 243.00 (48.79%) | 购买 | 174.96 | |
| RBC Capital | 08 Aug 2025 | 230.00 (40.83%) | 购买 | 191.49 |
| Stifel | 08 Aug 2025 | 254.00 (55.52%) | 购买 | 191.49 |
| UBS | 08 Aug 2025 | 307.00 (87.97%) | 购买 | 191.49 |
| Wedbush | 08 Aug 2025 | 220.00 (34.70%) | 购买 | 191.49 |
| Wells Fargo | 08 Aug 2025 | 295.00 (80.63%) | 购买 | 191.49 |
| JP Morgan | 29 Jul 2025 | 254.00 (55.52%) | 购买 | 163.32 |
| Morgan Stanley | 03 Jul 2025 | 250.00 (53.07%) | 购买 | 174.18 |
| Oppenheimer | 13 Jun 2025 | 224.00 (37.15%) | 购买 | 170.80 |
| B of A Securities | 09 Jun 2025 | 216.00 (32.26%) | 购买 | 173.15 |
| 03 Jun 2025 | 201.00 (23.07%) | 购买 | 174.40 | |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合